Information Provided By: 
Fly News Breaks for September 16, 2019
XLRN
Sep 16, 2019 | 22:05 EDT
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $71 price target on Acceleron after its ACE-083 agent failed to meet its primary endpoint in the Phase 2 proof-of-concept facioscapulohumeral muscular dystrophy, or FSHD, trial. The analyst contends that the program was already high risk and that her model did not assign it any value, adding that she would buy any weakness in the stock given the company's other near-term catalysts are expected to drive "significant upside."
News For XLRN From the Last 2 Days
There are no results for your query XLRN
